Related Experiment Video
Updated: Apr 14, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic
Olivier Descamps1, Joanne E Tomassini2, Jianxin Lin2
1Centre de Recherche Médicale de Jolimont, 159, Rue Ferrer, 7100 Haine Saint-Paul, Belgium.
Insights
Ezetimibe plus statins showed lower relative variability in LDL-C lowering compared to statins alone in hypercholesterolemic patients. This combination therapy offers more predictable LDL-C reduction, aiding clinical decisions.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Hypercholesterolemia management relies on lipid-lowering therapies.
- Statins are first-line treatments, but response variability exists.
- Ezetimibe offers an alternative or add-on mechanism for LDL-C reduction.
Purpose of the Study:
- To compare the variability of low-density lipoprotein cholesterol (LDL-C) lowering responses between ezetimibe plus statins and statins alone.
- To analyze absolute and relative variability metrics in hypercholesterolemic patients.
Main Methods:
- Pooled analysis of patient-level data from 27 double-blind studies (21,671 patients).
- Comparison of LDL-C % change from baseline using standard deviation (SD), coefficient of variation (CV), and root mean squared error (RMSE).
- Evaluated first-line (statin-naïve) and second-line (add-on or uptitrate) treatment scenarios.
Main Results:
- Lower absolute variability (SD, RMSE) of LDL-C response with ezetimibe + statins versus statins in first-line and second-line add-on studies.
- Relative variability (CV) was consistently lower for ezetimibe + statins across all study types, particularly in second-line studies.
- Ezetimibe + statins demonstrated greater mean LDL-C reductions, contributing to lower relative variability.
Conclusions:
- Ezetimibe plus statins did not show greater absolute LDL-C response variability compared to statins alone.
- Relative variability of LDL-C reduction was lower with the combination therapy.
- Understanding response variability can guide therapeutic decisions for hypercholesterolemia.
Objective:
We compared the variability of LDL-C-lowering responses to treatment with ezetimibe + statins versus statins in hypercholesterolemic patients.
Methods:
An analysis of patient-level data pooled from 27 double-blind, placebo and/or active-controlled studies in 21,671 patients treated with ezetimibe + statins versus statins on first-line (statin-naïve/wash-out) or second-line (on statin, randomized to ezetimibe versus placebo [add-on] or ezetimibe versus uptitrated statin [uptitrate]) for 6-24 wks. Variances (standard deviation [SD], coefficient of variation [CV], and root mean squared error [RMSE] adjusted for various factors) for % change from baseline in LDL-C were compared.
Results:
In first-line and second-line add-on studies, the variability (SD, RMSE) of % change from baseline in LDL-C was lower in ezetimibe + statin-treated patients versus statin-treated patients, ±covariates. Differences were small but statistically significant due to the large sample size. In second-line uptitrate studies, ezetimibe + statin treatment resulted in greater unadjusted variability (SD) versus statin therapy, while the adjusted variability (RMSE) was significantly lower. Relative variability (CV=SD/mean) was lower for ezetimibe + statins versus statin therapy for all study types, being more pronounced in second-line add-on and uptitrate studies, attributed to larger mean LDL-C reductions for ezetimibe + statins versus statin groups. When assessed by individual study/type, statin brand, potency or dose, the CVs remained lower for ezetimibe + statins versus statins in second-line studies. The SDs showed no consistent trend for either therapy.
Conclusion:
In hypercholesterolemic patients, the absolute variability of LDL-C-lowering responses to ezetimibe + statins was not greater versus statins alone and appeared lower when adjusted for other factors. Relative variability was lower in patients treated with statins + ezetimibe. A better understanding of the variability of the LDL-C lowering response may help guide clinicians in making therapeutic decisions.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:24Dosage Regimen: Individualization
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment